ESMO® 2025 Highlights: Presenter Vignette – Alexandra Drakaki
Alexandra Drakaki
MD, PhD
University of California
3070MO
Phase 1 study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
